Share-based compensation. The increase in share-based compensation expense of $8.6 million for the quarter ended December 31, 2010 over the same quarter in 2009 reflected: (1) an increase in the fair value of awards granted under our Share Tracking Awards Plan (STAP), principally as a result of the increase in the price of our common stock; (2) an increase in the number of outstanding STAP awards; and (3) increases in both the number of STAP awards vested and the time that unvested STAP awards had accrued toward vesting as of December 31, 2010.
Other. Other research and development expenses increased $3.6 million during the quarter ended December 31, 2010 compared to the same quarter in 2009 reflected primarily an increase in personnel, depreciation and overhead costs supporting our research mainly because 2010 was the first full year of operations of our new facilities in North Carolina and Maryland. Research and development expenses for our individual disease platforms include only direct labor and related direct costs.
The table below summarizes selling, general and administrative expense by major categories (in thousands):Three Months EndedDecember 31,Year EndedDecember 31,2010200920102009CategoryGeneral and administrative
68,606Sales and marketing
|SOURCE United Therapeutics Corporation|
Copyright©2010 PR Newswire.
All rights reserved